Literature DB >> 30170940

Developing potential Helicobacter pylori urease inhibitors from novel oxoindoline derivatives: Synthesis, biological evaluation and in silico study.

Yu-Shun Yang1, Mi-Mi Su1, Xu-Ping Zhang1, Qi-Xing Liu1, Zhen-Xiang He2, Chen Xu3, Hai-Liang Zhu4.   

Abstract

By recruiting the important moiety from Shikonin, a series of novel oxoindoline derivatives S1-S20 have been synthesized for inhibiting H. pylori urease. The most potent compound S18 displayed better activity (IC50 = 0.71 μM; MIC = 0.48 μM) than the positive controls AHA (IC50 = 17.2 μM) and Metronidazole (MIC = 31.3 μM). With low cytotoxicity, it showed considerable potential for further development. Docking simulation revealed the possible binding pattern of this series. 3D QSAR model was built to discuss SAR and give useful hints for future modification.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3D QSAR; Antimicrobial; Helicobacter pylori; Molecular docking; Oxoindoline derivatives; Urease

Mesh:

Substances:

Year:  2018        PMID: 30170940     DOI: 10.1016/j.bmcl.2018.08.025

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Diagnostic approach to Helicobacter pylori-related gastric oncogenesis.

Authors:  Sebastian Rupp; Apostolis Papaefthymiou; Eleftherios Chatzimichael; Stergios A Polyzos; Stefan Spreitzer; Michael Doulberis; Thomas Kuntzen; Jannis Kountouras
Journal:  Ann Gastroenterol       Date:  2022-06-02

Review 2.  Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens.

Authors:  Sandra Salillas; Javier Sancho
Journal:  Int J Mol Sci       Date:  2020-03-10       Impact factor: 5.923

3.  Hydrazones of 4-(Trifluoromethyl)benzohydrazide as New Inhibitors of Acetyl- and Butyrylcholinesterase.

Authors:  Martin Krátký; Katarína Svrčková; Quynh Anh Vu; Šárka Štěpánková; Jarmila Vinšová
Journal:  Molecules       Date:  2021-02-13       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.